Quest Diagnostics Named to Fortune's Most Admired Companies List for 12th Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Newsfilter
- Industry Recognition: Quest Diagnostics has been named to Fortune's Most Admired Companies list for the 12th consecutive year, reflecting the commitment of its 55,000 employees to advancing health initiatives.
- Industry Ranking: The company secured the second position in the 'Health Care: Pharmacy and Other Services' category, further solidifying its leadership in the healthcare sector.
- Reputation Assessment: The recognition is based on nine key attributes, including product quality, innovation, long-term value, and social responsibility, showcasing Quest's outstanding performance in the industry.
- Market Impact: Annually, Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the U.S., with its diagnostic insights not only improving health outcomes but also driving transformative changes in healthcare management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 203.75 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardant Health's Optimistic Future Outlook
- Positive Financial Performance: Guardant Health achieved positive free cash flow in Q3 2025, one quarter ahead of its goal, indicating strong growth potential in its core oncology business, with expectations to maintain positive cash flow throughout 2026 and beyond, thereby boosting investor confidence.
- Strategic Collaboration Expansion: The company signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its market position in precision oncology.
- FDA Approval Milestone: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi and Eli Lilly's Erbitux in combination chemotherapy, marking its first FDA approval in colorectal cancer, enhancing the company's competitive edge in the market.
- Optimistic Market Outlook: Although the fourth-quarter financial results for 2025 have yet to be announced, investors maintain an optimistic view of Guardant Health's future, believing that the upcoming update could serve as a catalyst for stock price appreciation, although caution is advised against rushing into purchases in the short term.
Continue Reading
Guardant Health Stock Soars Amid New Collaborations
- Stock Performance: Guardant Health's stock has surged over the past six months, currently priced at $110.48 with a market cap of $14 billion, reflecting strong market confidence in its future growth potential.
- Collaboration Agreement: The company has signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its leadership in precision oncology.
- Positive Cash Flow: In Q3 2025, Guardant's core oncology business achieved positive free cash flow ahead of schedule, with management expecting to maintain this trend throughout 2026 and beyond, indicating significant operational efficiency improvements.
- FDA Approval: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi, marking its first FDA certification in colorectal cancer, which, while not impacting Q4 results, lays a solid foundation for future growth.
Continue Reading